انت هنا الان : شبكة جامعة بابل > موقع الكلية > نظام التعليم الالكتروني > مشاهدة المحاضرة

Lupus erythematosus 2

الكلية كلية الطب     القسم  الباطنية     المرحلة 5
أستاذ المادة علي محمد حسين خلف القزاز       6/6/2011 9:13:48 PM

 Lupus erythematosus

Is chronic auto immune disease

that can be fatal, though with recent medical advances, fatalities are becoming increasingly rare

the attacks the body’s cells and tissue, resulting in inflammation and tissue damage. SLE can affect any part of the body, but most often harms the, , , the skin ,joints ,lung .kidney ,blood vesseles and central nervous system.

The course of the disease is unpredictable, with periods of illness (called flares) alternating with remission.

Lupus can occur at any age, and is most common in women, particularly black young people

Lupus is treatable, mainly with stroid and immunosupresive  and, though there is currently no cure. However, many people with Lupus lead long and substantial lives

Classification:

systemic lupus erythematosus

drug induce lupus

Discoid lupus erythematosus

.  Subacute cutaneous lupus erythematosus

.  Neonatal lupus

Signs and symptoms SLE is one of several diseases known as "the great imitators. because its symptoms vary so widely it often mimics or is mistaken for other illnesses, and because the symptoms come and go unpredictably. Diagnosis can be elusive, with patients sometimes suffering unexplained symptoms and untreated SLE for years. Common initial and chronic complaints  fever malaise                       

,arthrlagia ,skin rash,fatigue ,mylagia .

                                .                                      

                                                         Dermatological manifestations

As many as 30% of patients present with some dermatological symptoms (and 65% suffer such symptoms at some point), with 30% to 50% suffering from the classic malar rash Patients may present with discoid lupus (thick, red scaly patches on the skin.alopacia,mouth,nasal and vaginal ulcer.

Musculoskeletal manifestations: Patients most often seek medical attention forjoint  pain 90% of them during the course of the illness with or with out muscle pain unlike RA lupus arthritis less disable with out distraction of the joint few than 10% have joint deformites of hand and feet.

 

 

  Hematological manifestations

Anemia and iron deficiency may develop in as many as half of patients and low platelets and WBC may be due to the disease or a side-effect of pharmacological treatment. patients may have antiphosphlipid syndrome with thrombosis where autoantibodies to phospholipids are present in the patient s serum. Abnormalities associated with antiphospholipid antibody syndrome include a paradoxical prolonged PTT (which usually occurs in hemorrhagic disorders) and a positive test for antiphospholipid antibodies with anticardiolipin may be positive and false positive VDRL.   

Cardiac manifestations

Patients may present with inflammation of various parts of the OF THE HEART like myocarditis, endocarditis and pericarditis , endocarditis of SLE is characteristically non-infective[libman-sacks]mostly involve mitral and tricaspid.atherosclrosis occur more in SLE patients.

              

                                                                          

Pulmonary manifestations

Like plurtic involvement and hemmorgic lung, intersial fibrosis and infection .pulmonary infraction and hypertension.

 

Renal invlovment: one of the major that involved in SEL and cause morbidity and mortality after infection. and lead to hypertension ,it manifested by edema and oliguria and diagnosed by GUE where found RBC cast ,granular cast, and proteinuria with increased creatinine and blood urea, Because of early recognition and management of SLE, end stage renal failure occurs in less than 5% of patients.

There are six stages of renal involvement.

 

  Neurological manifestations

10% have CNS affection manifested by seizer or psychological abnormities or headache and septic meningitis.

Other:

Systemic vasculitis , GIT involvement, lupus cystitis, and pancreatis.

 

Causes

Still the cause unknown. its chronic inflammatory disease ,type three hypersensitivity,with potential type 2 involvement. characterised by the body s production of antibodies against the nuclear components of its own cells. There are three mechanisms by which lupus is thought to develop: genetic predisposition, environmental triggers and drug reaction (drug-induced lupus).

 Genetics

Lupus run in families, but no single "lupus gene" has yet been identified. Instead, multiple genes appear to influence a person s chance of lupus developing when triggered by environmental factors. The most important genes are located at 6 chromosome. where mutations may occur randomly .

Environmental triggers

The second mechanism may be due to environmental factors. These factors may not only exacerbate existing lupus conditions, but also trigger the initial onset. They include certain medications like antidepressant and antibiotics , extreme stress, exposure to sunlight, hormones, and infections. Some researchers have sought to find a connection between certain infectious agents like bacteria or virus but no pathogen is linked. UV radiation has been shown to trigger the photosensitive lupus rash, but some evidence also suggests that UV light is capable of altering the structure of the DNA, leading to the creation of auto antibodies.

  Drug reactions

 is a reversible condition that usually occurs in patients being treated for a long-term illness. Drug-induced lupus mimics systemic lupus. However, symptoms of drug-induced lupus generally disappear once a patient is taken off the medication which triggered the episode. There are about 400 medications currently in use that can cause this condition, though the most common drugs,procaimaide,hydralzine and quindine.

 

  

  Non-SLE forms of lupus

Discoid (cutaneous) lupus is limited to skin symptoms and is diagnosed via biopsy of skin rash on the face, neck or scalp and ANF USUALLY negative ,10% change to SLE.

Path physiology

 

a disturbance of the normal functioning of the body. One manifestation of lupus is abnormalities in apoptosis, a type of programmed cell death in which aging or damaged cells are neatly disposed of as a part of normal growth or functioning.

 

Diagnosis

Some physicians make a diagnosis on the basis of the ACR classification criteria but other used it for researches only . and patients may have lupus but never meet the full criteria.

patients must meet the following three criteria to be classified as having SLE: (i) patient must present with four of the below eleven symptoms (ii) either simultaneously or serially (iii) during a given period of observation.

1- malar rash

2-..Discoid lupus

3-Discoid lupus

4-Oral ulcers: include oral or nasopharyngeal ulcers

5-Arthritis: nonerosive arthritis of two or more peripheral joints, with tenderness, swelling or effusion

6-Renal disorder: More than 0.5 g per day protein in urine, or cellular cast seen in urine under a microscope.

7- Neurologic disorder , Seizuresor psychosis

8- Serositis: Pleuritis,pericarditis

9-Hematologic disorder, Hemolytic anemia, leukopenia, white blood cell count<4000/ul), lymphopenia, ( <1500/ul ), thrombocytopenia, (<100000/uL) in the absence of offending drug.

Hypocomplementemia is also seen, due to either consumption of C3 and C4 by immune complex-induced inflammation, or to congenitally complement deficiency, which may predispose to SLE

10-Anti-nuclear antibody, test positive, sensitivity99%,specificity45%.

11-Immunologic disorder: Positive, anti-Sm,antidsDNA, anti-phospholipid antibody, false positiveVDRL test.

Some patients, especially those with antiphospholipid syndrome, may have SLE without four criteria and SLE.

Common misdiagnoses; Porphyria

Common dual diagnoses; RA,SCURVY, FIFROMYLGIA.

 

Drug therapy:

Due to the variety of symptoms and organ system involvement with Lupus patients, the severity of the SLE in a particular patient must be assessed in order to successfully treat SLE. Mild or remittent disease can sometimes be safely left untreated. If required, non-steroidal anti-inflammatory drug and anti-malarials may be used.

Disease-modifying antirheumatic drugs (DMARDs) are used preventively to reduce incidence of flares, the process of the disease, and lower the need for steroid use; when flares occur, they are treated with corticosteroids. DMARDs commonly in use are anti-malarials and immunosuppressants (e.g. methotrexate and azathioprine). Hydroxychloroquine (trade name Plaquenil) is an FDA approved anti-malarial used for constitutional, cutaneous, and articular manifestations, while Cyclophosphamide (trade names Cytoxan and Neosar) is used for severe glomerulonephritis or other organ-damaging complications, and in 2005, mycophenolic acidCellCept became accepted for treatment of lupus nephritis.

In more severe cases, medications that modulate the immune system (primarily corticosteroids and Immunosuppresive drug immunosuppressants) are used to control the disease and prevent re-occurrence of symptoms (known as flares). Patients who require steroids frequently may develop obesity, diabetes mellitus diabetes and osteoporosis. Depending on the dosage, corticosteroids can cause other side effects such as a puffy face, an unusually large appetite and difficulty sleeping. Those side effects can subside if and when the large initial dosage is reduced, but long term use of even low doses can cause elevated blood pressure and cataracts. Due to these side effects, steroids are avoided if possible.

Since a large percentage of Lupus patients suffer from varying amounts of chronic pain, stronger prescription analgesics may be used if over-the-counter drugs, mainly non-steroidal anti-inflammatory drug do not provide effective relief. Moderate pain in Lupus patients if typically treated with mild prescription opiates such as Dextropropoxyphene (trade name Darvocet), and Co-codamol (trade name Tylenol #3). Moderate to severe chronic pain is treated with stronger opioids such as Hydrocodone (trade names Lorcet, Lortab, Norco, Vicodin, Vicoprofen) or longer-acting continuous release opioidssuch as Oxycodone (trade names OxyContin), MS Contin, or Methadone. The Fentanyl Duragesic Transdermal patch is also a widely-used treatment option for chronic pain due to Lupus complications because of its long-acting timed release and easy usage. When opioids are used for prolonged periods drug tolerance, chemical dependency and (rarely) addiction may occur. Opiate addiction is not typically a concern for Lupus patients, since the condition is not likely to ever completely disappear. Thus, lifelong treatment with opioids is fairly common in Lupus patients that exhibit chronic pain symptoms; accompanied by periodic titration that is typical of any long-term opioid regimen.

Lifestyle changes:

Other measures such as avoiding sunlight or covering up with sun protective clothing can also be effective in preventing problems due to photosensitivity. Weight loss is also recommended in overweight and obese patients to alleviate some of the effects of the disease, especially where joint involvement is significant.

Treatment Research

Other immunosuppressants(A drug that lowers the body s normal immune response) and bone marrow transplant autologous stem cell transplants are under investigation as a possible cure. Recently, treatments that are more specific in modifying the particular subset of the immune cells (e.g. B- or T- cells) or cytokine

Prevention:

While most infants born to mothers with lupus are healthy, pregnant mothers with SLE should remain under a doctor s care until delivery. Neonatal lupus is rare, but identification of mothers at highest risk for complications allows for prompt treatment before or after birth. In addition, SLE can flare during pregnancy and proper treatment can maintain the health of the mother for longer. Women pregnant and known to have the antibodies for anti-Ro (SSA) or anti-La (SSB) should have echocardiograms during the 16th and 30th weeks of pregnancy to monitor the health of the heart and surrounding vasculature

 

Prognosis:

In the 1950s, most patients diagnosed with SLE lived fewer than five years. Advances in diagnosis and treatment have improved survival to the point where over 90% of patients now survive for more than ten years and many can live relatively asymptomatically. The most common cause of death is infection due to immunosuppression, as a result of medications used to manage the disease. Prognosis is normally worse for men and children than for women. Fortunately, if symptoms are present after age 60, the disease tends to run a more benign course. The ANA is the most sensitive screening test and ANTI Sm [antismith] is the most specific and the anti Ds-DNA antibody is also fairly specific and often fluctuates with disease activity. The ds-DNA titer is therefore sometimes useful to diagnose or monitor acute flares or response to treatment.

 

Epidemiology:

In the United States alone, it is estimated that between 270,000 and 1.5 million people have lupus, making it more common than cystic fibrosis or cerebral palsy. The disease affects both females and males, though young women are diagnosed nine times more often than men. SLE occurs with much greater severity among African-American women, who suffer more severe symptoms as well as a higher mortality rate, Worldwide, a conservative estimate states that over 5 million people have lupus.

Although SLE can occur in anyone at any age, it is most common in women of childbearing age. It affects 1 in 4000 people in the United States, with women becoming afflicted far more often than men. The disease appears to be more prevalent in women of African, Asian, Hispanic and Native American origin but this may be due to socioeconomic factors.

 

 

 

 

 


المادة المعروضة اعلاه هي مدخل الى المحاضرة المرفوعة بواسطة استاذ(ة) المادة . وقد تبدو لك غير متكاملة . حيث يضع استاذ المادة في بعض الاحيان فقط الجزء الاول من المحاضرة من اجل الاطلاع على ما ستقوم بتحميله لاحقا . في نظام التعليم الالكتروني نوفر هذه الخدمة لكي نبقيك على اطلاع حول محتوى الملف الذي ستقوم بتحميله .